Related Experiment Video
Updated: Sep 28, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Accelerated hepatitis B vaccination schedule in childhood
Mehmet Bosnak1, Bunyamin Dikici, Vuslat Bosnak
1Department of Pediatrics, Dicle University Medical School, Diyarbakir, Turkey. mbosnak@dicle.tr
Insights
An accelerated hepatitis B vaccine schedule (0, 10, 21 days) provides rapid protection for children traveling to endemic areas. This rapid HBV immunization offers similar long-term protection to the standard schedule.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- The standard hepatitis B virus (HBV) vaccination schedule is lengthy, posing challenges for children requiring timely immunization.
- Accelerated HBV vaccination is crucial for children traveling to endemic regions or needing blood products.
Purpose of the Study:
- To evaluate the efficacy of an accelerated HBV vaccination schedule in children.
- To compare rapid HBV immunization with the conventional schedule.
Main Methods:
- Forty children were randomized into two groups: accelerated (0, 10, 21 days) and conventional (0, 1, 6 months) HBV vaccination.
- Blood samples were collected at 1, 6, and 12 months post-vaccination for serological analysis.
Main Results:
- The accelerated schedule showed significantly higher seroconversion rates at 1 month (80% vs. 35%) and day 28 (P < 0.005).
- Seroprotection rates at 1 month were higher with the accelerated schedule (65% vs. 20%).
- Both schedules achieved comparable seroprotection rates (95%) by 12 months.
Conclusions:
- An accelerated 3-week HBV vaccination regimen elicits protective anti-HBs antibodies faster than the standard schedule.
- The accelerated schedule is recommended for HBV prophylaxis in children with limited time before travel or potential exposure.
- No significant difference in long-term seroprotection was observed between the schedules after one year.
Background:
For children travelling to a hepatitis B virus (HBV) endemic area or before a treatment by blood or blood productions, the conventional HBV vaccination schedule takes too long to be completed. There may be problems in the completion of the whole vaccination schedule in developing countries because of particular problems. In these situations an accelerated schedule may be useful for HBV vaccination.
Methods:
In this study, 40 children were randomly divided into two groups. Groups were vaccinated according to two different schedules; schedule A: one dose at 0, 1, and 6 months and schedule B: one dose at 0, 10, and 21 days (Engerix B, 10 mcg/0.5 ml, GlaxoSmithKline). Follow-up blood samples were obtained at 1, 6 and 12 months after the first vaccine injection.
Results:
Seroconversion rates were 35 and 80% 1 month after the first vaccine injection, 95 and 80% at 6 months, 95 and 100% at 12 months, in groups A and B respectively. Seroprotection rates were 20 and 65% 1 month after the first vaccine injection, 85 and 70% at 6 months, 95 and 95% at 12 months, in groups A and B respectively. Seroconversion and seroprotection rates was significantly different at day 28 in accelerated vaccination schedule (P < 0.005).
Conclusions:
In conclusion, an accelerated vaccination course against HBV (three doses at 0, 10, and 21 days) elicited protective levels of anti-HBs antibodies more rapidly than a classic course (three doses at 0, 1, and 6 months) and without a difference in the rate of seroprotection after 1 year. The accelerated 3-week recombinant HBV vaccination schedule should be recommended for HBV prophylaxis when children, such as hurried travellers, who have to have blood and blood productions, or an estimated irregular vaccination, where they have < 1 month to complete the standard HBV vaccination schedule before travelling to HBV endemic areas.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Vaccinations
Yellow Fever
Chickenpox
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...